UBS AM
CTIC

UBS AM’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

UBS AM’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-92,700
Closed -$389K – 2759
2023
Q2 		$389K Hold
92,700
– – ﹤0.01% 2397
2023
Q1 		$389K Buy
92,700
+17,000
+22% +$88.2K ﹤0.01% 2397
2022
Q4 		$455K Buy
+75,700
New +$413K ﹤0.01% 2206
2016
Q2 		– Sell
-11,290
Closed -$60K – 2680
2016
Q1 		$60K Hold
11,290
– – ﹤0.01% 2606
2015
Q4 		$139K Buy
11,290
+1,870
+20% +$25K ﹤0.01% 2622
2015
Q3 		$138K Hold
9,420
– – ﹤0.01% 2565
2015
Q2 		$184K Hold
9,420
– – ﹤0.01% 2604
2015
Q1 		$171K Hold
9,420
– – ﹤0.01% 2519
2014
Q4 		$222K Hold
9,420
– – ﹤0.01% 2422
2014
Q3 		$228K Buy
9,420
+5,020
+114% +$131K ﹤0.01% 2305
2014
Q2 		$124K Buy
+4,400
New +$132K ﹤0.01% 2505

UBS AM's CTIC Position: Q3 2023 in Review

UBS AM sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q3 2023, closing a stake of 92,700 shares — an estimated $389K sold.

UBS AM first reported a position in CTIC in Q2 2014 and held it in 11 quarters. The position peaked at $455K in Q4 2022. 0 funds tracked by Wall St. Rank hold CTIC as of Q3 2023.

  • UBS AM reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q3 2023 after selling out during the quarter.
  • UBS AM sold 92,700 CTI BioPharma Corp. (DE) Common Stock shares in Q3 2023, an estimated $389K.
  • UBS AM first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2014 and held it in 11 quarters.
  • UBS AM's CTI BioPharma Corp. (DE) Common Stock position peaked at $455K in Q4 2022.
  • 0 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q3 2023.

Based on UBS AM's 13F filing for Q3 2023, filed 13 Nov 2023.